The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA).
J. De Castro
No relevant relationships to disclose
M. Domine
No relevant relationships to disclose
J. Garcia-Bueno
No relevant relationships to disclose
S. Saura
No relevant relationships to disclose
R. GarcĂ­a
No relevant relationships to disclose
M. Sereno
No relevant relationships to disclose
O. Juan Vidal
No relevant relationships to disclose
E. Pujol
No relevant relationships to disclose
B. Rubio-Viqueira
No relevant relationships to disclose
M. Cobo
No relevant relationships to disclose